MSB 7.34% $2.12 mesoblast limited

Ann: FDA Agrees to Rolling Review of Mesoblast BLA Submission, page-2

  1. 6,582 Posts.
    lightbulb Created with Sketch. 858
    Well we now know they have had the meeting, but as for the rest IMO we already knew all of this ?  

    New York, USA; and Melbourne, Australia, April 16, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, announced today that the United States Food and Drug Administration (FDA) has agreed that Mesoblast can submit on a rolling basis a Biologics License Application (BLA) for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease (SR-aGVHD).

    Mesoblast will submit each module of the BLA to the FDA on a rolling basis as it is completed. The rolling process will provide opportunity for ongoing and frequent communication, and during this process the Company expects it will be able to adequately address any substantial matters raised by the FDA.

    Mesoblast has previously received Fast Track designation from the FDA for remestemcel-L in SRaGVHD and is eligible for priority review once the BLA filing is completed and accepted by the FDA. Mesoblast expects to submit the first module shortly.
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.057B
Open High Low Value Volume
$1.98 $2.18 $1.94 $7.309M 3.560M

Buyers (Bids)

No. Vol. Price($)
3 19495 $2.12

Sellers (Offers)

Price($) Vol. No.
$2.13 102 1
View Market Depth
Last update - 16.10pm 13/09/2019 (20 minute delay) ?
0.145 ( 7.65 %)
Open High Low Volume
$1.98 $2.18 $1.95 330721
Last updated 15.59pm 13/09/2019 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.